Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Autor: Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A.S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J.U., Kobe, C., Eich, H.-T., Baues, C., Fuchs, M., Borchmann, P., Behringer, K.

Publikováno v: In Annals of Oncology March 2024 35(3):276-284

Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.

Autor: Rosenbrock J; German Hodgkin Study Group (GHSG); Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Electronic address: Johannes.Rosenbroc@uk-koeln.de., Kaul H; German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Oertel M; German Hodgkin Study Group (GHSG); Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Celik E; Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Linde P; Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Fan J; Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Eichenauer DA; German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Bröckelmann PJ; German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., von Tresckow B; German Hodgkin Study Group (GHSG); Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Kobe C; German Hodgkin Study Group (GHSG); Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Dietlein M; German Hodgkin Study Group (GHSG); Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Fuchs M; German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Borchmann P; German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Eich HT; German Hodgkin Study Group (GHSG); Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Baues C; German Hodgkin Study Group (GHSG); Department of Radiation Oncology, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Dec 01; Vol. 120 (5), pp. 1344-1352. Date of Electronic Publication: 2024 Apr 15.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Autor: Borchmann P; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany. Electronic address: peter.borchmann@uk-koeln.de., Ferdinandus J; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Schneider G; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Moccia A; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Oncology Institute of Southern Switzerland, EOC, Medical Oncology, Bellinzona, Switzerland., Greil R; 3rd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria., Hertzberg M; Prince of Wales Hospital Department of Haematology and University NSW, Sydney, NSW, Australia; Australasian Leukaemia & Lymphoma Group, Melbourne, VIC, Australia., Schaub V; University of Tübingen, Tübingen, Germany., Hüttmann A; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany., Keil F; Department of Haematology, Hanusch Krankenhaus, Vienna, Austria., Dierlamm J; University Hospital Hamburg-Eppendorf, Hamburg, Germany., Hänel M; Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany., Novak U; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Department of Medical Oncology, University Hospital Bern, Bern, Switzerland., Meissner J; Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany., Zimmermann A; Department of Hematology and Oncology, Klinikum Leverkusen, Leverkusen, Germany., Mathas S; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Berlin, Germany; Humboldt University of Berlin, Berlin Institute of Health, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, Berlin, Germany; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Zijlstra JM; Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands., Fosså A; Department of Oncology, Oslo University Hospital, Oslo, Norway; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany., Viardot A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany., Martin S; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany., Giri P; Department of Haematology and Bone Marrow Transplant, Royal-Adelaide-Hospital, Adelaide, SA, Australia., Scholl S; Klinik für Innere Medizin II, Jena University Hospital, Jena, Germany., Topp MS; Department of Internal Medicine II, Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany., Jung W; Department of Haematology and Oncology, Göttingen, Germany., Vucinic V; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany., Beck HJ; Department of Medicine III, Universitätsmedizin Mainz, Mainz, Germany., Kerkhoff A; Department for Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, Muenster, Germany., Unger B; Hämatologie, Onkologie und Tumorimmunologie, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Rank A; Department of Internal Medicine II, University Hospital Augsburg, Augsburg, Germany., Schroers R; Department of Hematology and Oncology, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, Germany., Zum Büschenfelde CM; Clinic for Hematology, Oncology, Immunology and Palliative Medicine, Vincentius-Deaconry Clinics gAG, Karslruhe, Germany., de Wit M; Clinic for Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany., Trautmann-Grill K; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Kamper P; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Hematology, University Hospital of Aarhus, Aarhus, Denmark., Molin D; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden., Kreissl S; Ordensklinikum Linz Elisabethinen, Linz, Austria., Kaul H; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., von Tresckow B; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany., Borchmann S; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Behringer K; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Fuchs M; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Rosenwald A; Institute for Pathology, University Hospital Würzburg, Würzburg, Germany., Klapper W; Karl Lennert Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany., Eich HT; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany., Baues C; Department of Radiation Oncology, University Hospital of Ruhr-Universität Bochum, Marien Hospital Herne, Herne, Germany., Zomas A; Global Medical Lead for Lymphoma & Leukemia at Takeda Oncology, Cambridge, MA, USA., Hallek M; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany., Dietlein M; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Kobe C; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Diehl V; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany.

Publikováno v: Lancet (London, England) [Lancet] 2024 Jul 27; Vol. 404 (10450), pp. 341-352. Date of Electronic Publication: 2024 Jul 03.

Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.

Autor: Ferdinandus J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Gleueler Straße 269-273, 50935, Cologne, Germany. justin.ferdinandus@uk-koeln.de.; German Hodgkin Study Group (GHSG), Cologne, Germany. justin.ferdinandus@uk-koeln.de., van Heek L; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany., Roth K; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany., Dietlein M; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany., Eich HT; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Radiation Oncology, University Hospital Münster, Münster, Germany., Baues C; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Radiotherapy and Cyberknife Center, University Hospital Cologne, Cologne, Germany.; Department of Radiooncology, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany., Borchmann P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Gleueler Straße 269-273, 50935, Cologne, Germany.; German Hodgkin Study Group (GHSG), Cologne, Germany., Kobe C; German Hodgkin Study Group (GHSG), Cologne, Germany.; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jan; Vol. 51 (2), pp. 490-495. Date of Electronic Publication: 2023 Sep 22.

Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC – a Randomised Controlled Prospective Multicentre Phase III Trial

Autor: Brunner, T.B., Lordick, F., Schmoor, C., Schmidberger, H., Kirste, S., Rieken, S., Petersen, C., Nicolay, N.H., Fokas, E., Dunst, J., Rades, D., Eble, M.J., Krause, M., Roedel, C., Medenwald, D., Niehoff, P., Wittig-Sauerwein, A., Baues, C., Grosu, A., Hoeppner, J.

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 October 2024 120(2) Supplement:S6-S6